Trius Therapeutics, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares for Common Stock Offering

        Print
| Source: Trius Therapeutics, Inc.

SAN DIEGO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full their option to purchase an additional 1,290,000 shares of common stock. With the sale of the additional shares at a price to the public of $5.25 per share, the aggregate gross proceeds to Trius from this offering are expected to be approximately $51.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 31, 2012, subject to customary closing conditions. 

Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses.

Citigroup and Piper Jaffray & Co. are acting as joint book-running managers and Canaccord Genuity Inc. and Ladenburg Thalmann & Co. Inc. are acting as co-managers in the offering. The securities described above were offered by Trius pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on September 15, 2011. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained, when available, from Citigroup, Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, at 1-800-831-9146 and at batprospectusdept@citi.com or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at prospectus@pjc.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. 

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the three preclinical programs fully supported by federal contracts. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Trius' expectations regarding the closing of the public offering and the expected gross proceeds therefrom. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Trius' business and finances in general, and the other risks described in Trius' Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, and in the prospectus supplement related to the offering filed with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Public Relations Contact:
Jason Spark at Canale Communications, Inc.

619-849-6005

Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC

443-213-0507